Embecta Corp. $EMBC Stake Boosted by Isthmus Partners LLC

Isthmus Partners LLC lifted its holdings in Embecta Corp. (NASDAQ:EMBC) by 3.9% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 115,975 shares of the company’s stock after buying an additional 4,361 shares during the quarter. Isthmus Partners LLC owned approximately 0.20% of Embecta worth $1,124,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Banque Transatlantique SA raised its stake in Embecta by 879.1% during the first quarter. Banque Transatlantique SA now owns 3,701 shares of the company’s stock worth $44,000 after acquiring an additional 3,323 shares during the period. Brooklyn Investment Group boosted its stake in Embecta by 1,164.1% in the first quarter. Brooklyn Investment Group now owns 3,590 shares of the company’s stock valued at $46,000 after acquiring an additional 3,306 shares during the period. CWM LLC grew its holdings in shares of Embecta by 16.0% during the second quarter. CWM LLC now owns 8,080 shares of the company’s stock valued at $78,000 after purchasing an additional 1,115 shares during the last quarter. Neuberger Berman Group LLC acquired a new stake in shares of Embecta during the 1st quarter worth approximately $143,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Embecta by 7.9% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after purchasing an additional 1,093 shares during the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Zacks Research downgraded Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. BTIG Research reissued a “buy” rating on shares of Embecta in a report on Tuesday, November 25th. Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Embecta has an average rating of “Hold” and a consensus price target of $18.50.

Embecta Stock Performance

Shares of EMBC opened at $12.26 on Tuesday. Embecta Corp. has a one year low of $9.20 and a one year high of $21.48. The stock’s fifty day moving average is $13.87 and its 200-day moving average is $12.50. The firm has a market capitalization of $717.04 million, a price-to-earnings ratio of 7.52 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.04. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The business had revenue of $263.30 million during the quarter, compared to the consensus estimate of $265.66 million. During the same quarter in the prior year, the company posted $0.45 earnings per share. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Friday, December 5th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 4.9%. The ex-dividend date of this dividend is Friday, December 5th. Embecta’s dividend payout ratio (DPR) is presently 36.81%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.